Form D · Pharmaceuticals
Fedora Pharmaceuticals Inc.
Edmonton, A0 · CIK 0001576423
Offering snapshot reported Jun 6, 2025 · SEC filing
- Reported sold
- $895K Offering amount: $7.24M
- Investors reported
- 10 Form D · investor count
- Minimum accepted
- $69.6K Reported outside-investor minimum
- First sale
- Apr 25, 2025 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jun 6, 2025 | Initial | $895,076 | No comparison | 10 | SEC filing |
| May 10, 2013 | Initial | $200,100 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity, Other
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-548229
Class "B" Voting Common Shares
Source: Form D, filed Jun 6, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Sarat Maharaj | Director |
| Christopher Micetich | Director, Executive |
| Ronald Odynsk | Director |
| Leonard Post | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
11629 105 Avenue Nw
Edmonton, A0, T5H 092
Phone: (708) 761-0561
Edmonton, A0, T5H 092
Phone: (708) 761-0561